Catalog No. A8194

ABT-199

Name: ABT-199,维奈妥拉,Venetoclax,1257044-40-8
Brand: APExBIO
SKU: A8194
Price: 750 CNY
Availability: InStock

（别名：Venetoclax, 维奈妥拉）

选择性的Bcl-2抑制剂

规格	价格	货期
1mL(10 mM in DMSO)	￥750.00	现货
5mg	￥548.00	现货
50mg	￥980.00	现货

CAS号：1257044-40-8纯度：98.17%

仅用于科研，不用于诊疗。未经明确授权不得转售。

021-55669583sales@apexbio.cnAPExBIO

特色产品

Annexin V-FITC/PI Apoptosis Kit

用于双染检测细胞凋亡和坏死

- 在10-20分钟内完成染色
- 适用于流式细胞仪和荧光显微镜检测
- 准确区分活细胞/凋亡细胞/坏死细胞

Phos binding reagent (Phosbind) acrylamide

分离和检测磷酸化/非磷酸化蛋白

- 新型的磷酸盐结合标签和功能分子
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白

Cell Counting Kit-8 (CCK-8)

用于细胞增殖和细胞毒性试验

- 比MTT，MTS或WST-1更敏感
- 对细胞无毒性
- 步骤更简单，无需有机溶剂

Cy5 TSA Fluorescence System Kit

Cy5荧光标记的酪胺信号放大系统

- 检测ICC/IHC/ISH中的低丰度靶点
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率

EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

用于观察mRNA运送，定位，翻译

- 具有Cap1结构的荧光素酶mRNA
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰

HotStart™ 2X Green qPCR Master Mix

用于荧光定量目标DNA或cDNA

- 通过热启动机制优化扩增特异性
- 优异的扩增效率、可重复性和稳定性
- 卓越的灵敏度和准确性，操作简单

HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit Plus

高效的Cy5修饰RNA转录试剂盒

- 适合原位/Northernblot杂交实验
- 优化的缓冲液和T7 RNA聚合酶混合物
- 20 μL反应体系可获得更高的RNA产量

产品描述产品性质产品应用生物相关数据质量控制操作说明产品引用文献摩尔浓度计算器

产品描述

ABT-199是通过基于结构的逆向过程而研发的，是一种新型的特异性BCL-2抑制剂，具有低浓度的亲和力。ABT-199通过抑制细胞凋亡的线粒体途径，从而杀死非霍奇金淋巴瘤（NHL）和急性骨髓性白血病细胞系，以及BCL-2依赖而非BCL-XL依赖性的细胞，展示了对一系列血液系统肿瘤的抗肿瘤活性，同时保留了血小板。据报道，在几种人类血液系统肿瘤的异种移植模型中，ABT-199能够抑制肿瘤的生长。

参考文献：
Matthew S. Davids and Anthony Letai. ABT-199: a new hope for selective BCL-2 inhibition. Cancer Cell 2013; 23(2): 139-141

产品性质

物理外观	A solid
CAS号	1257044-40-8
分子式	C₄₅H₅₀ClN₇O₇S
分子量	868.44
小分子别名	Venetoclax
化学名称	4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
溶解度	≥43.42 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
SMILES	CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
存储条件	-20°C
运输条件	蓝冰

产品应用 (实验数据来自文献，APExBIO并未验证，仅供参考)

IC50和靶点

生物活性描述	ABT-199 (GDC-0199)是一种选择性的Bcl-2抑制剂，Ki值<0.01 nM, 比对Bcl-xL和Bcl-w的选择性高4800倍。
靶点	Bcl-2
生物活性数据	< 0.010 nM (Ki)

生物相关数据

质量控制

请选择批次查看:

纯度 = 98.17%

COA (Certificate Of Analysis)HPLC NMR (Nuclear Magnetic Resonance)MSDS (Material Safety Data Sheet)

操作说明

Datasheet 小分子化合物通用使用指南

APExBIO 顾客使用本产品发表的 35 篇科研文献

1. Anmbreen Jamroze, Xiaozhuo Liu, et al. "Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer." Signal Transduct Target Ther. 2026 May 1;11(1):161. PMID: 42067541

2. Nawal Merjaneh, Ying-Wei Lan, et al. "FOXM1 inhibitor, RCM‑1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma." Int J Oncol. 2026 May;68(5):52. PMID: 41789627

3. Nicholas W Harper, Gavin A Birdsall, et al. "RNA Pol II inhibition activates cell death independently from the loss of transcription." Cell. 2025 Aug 14:S0092-8674(25)00856-6. PMID: 40818455

4. R Taylor Ripley, Yuan Xu, et al. "Co-Targeting Bcl-xL with Mcl-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma." Mol Cancer Ther. 2025 Aug 14. PMID: 40804773

5. Rebecca A. DeStefanis, Alexa E. Schmitz, et al. "BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer." Mol Cancer Ther. 2025 Jul 10. PMID: 40635161

6. Shilpa Gurung, Timothy Budden, et al. "Stromal lipid species dictate melanoma metastasis and tropism." Cancer Cell. 2025 Jun 9;43(6):1108-1124.e11. PMID: 40280124

7. Nicholas W. Harper, Gavin A. Birdsall et al. "Pol II degradation activates cell death independently from the loss of transcription." bioRxiv. 2025 Jan 14:2024.12.09.627542. PMID: 39713309

8. Chase M. Carver, Sonia L. Rodriguez, et al. "IL-23R is a senescence-linked circulating and tissue biomarker of aging." Nature Aging volume 5, pages291–305 (2025)

9. Megan E Honeywell, Marie S Isidor, et al. "Functional genomic screens with death-rate analyses reveal mechanisms of drug action." Nat Chem Biol. 2024 Nov;20(11):1443-1452. PMID: 38480981

10. Romo, Bianca A, et al. "Estrogen Receptor (ER) Alpha Regulatory Mechanisms and Therapeutic Strategies in ER+ Breast Cancer." (2024). Dartmouth College Ph.D Dissertations. 182

11. Chase M Carver, Paul T Gomez, et al. "Senescent and disease-associated microglia are modifiable features of aged brain white matter." Res Sq. 2023 Oct 30:rs.3.rs-3467812. PMID: 37961365

12. Byeongwook Jeon, Yun Ji Lee, et al. "A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting." Am J Cancer Res. 2023 Feb 15;13(2):452-463. eCollection 2023. PMID: 36895970

13. Linlin Gu, Ranu Surolia, et al. "Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling." Cell Death Differ. 2022 Jan;29(1):118-132. PMID: 34413485

14. Schwartz, Hannah, et al. "In vitro Methods to Better Evaluate Drug Responses in Cancer." UMass Chan Medical School. September 8, 2022

15. Rana Estaleen. "Characterizing Senescence Induction and Senolytic Sensitivity in Murine Lung Cancer Cell Lines." Virginia Commonwealth University. May 10, 2022

16. Valerie Carpenter, Tareq Saleh, et al. "Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy." Biochem Pharmacol. 2021 Nov;193:114765. PMID: 34536356

17. Kirsteen J. Campbell, Susan M. Mason, et al. "Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function." Cell Death Differ. 2021 Sep;28(9):2589-2600. PMID: 33785871

18. Enyuan Shang, Trang T. T. Nguyen, et al. "Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma." Cancers 2020, 12(8), 2137;1 August 2020. PMID: 32752193

19. Meyer L, Verbist KC, et al. "JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation." Blood. 2020;blood.2020006075. PMID: 32530039

20. Shahbandi A, Rao SG, et al. "BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer." Cell Death Differ. 2020. PMID: 32457483

21. Meyer LK, Huang BJ, et al. "Glucocorticoids paradoxically facilitate steroid resistance in T-cell acute lymphoblastic leukemias and thymocytes." J Clin Invest. 2019 Nov 5. pii: 130189. PMID: 31687977

22. Thompson PJ, Shah A, et al. "Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes." Cell Metab. 2019 Feb 14. pii: S1550-4131(19)30021-X. PMID: 30799288

23. Minagawa K, Al-Obaidi M, et al. "Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy." Methods Mol Biol. 2019;1895:57-73. PMID: 30539529

24. Wu S, Fatkhutdinov N, et al. "SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells." Nat Commun. 2018 Oct 8;9(1):4116. PMID: 30297712

25. Li Q, Deng Q, et al. "Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses." Nat Commun. 2018 Sep 6;9(1):3600. PMID: 30190514

26. Kim SR, Lewis JM, et al. "BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition." Oncotarget.2018 Jun 26;9(49):29193-29207. PMID: 30018745

27. Tuzlak S, Haschka MD, et al. "Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis." FEBS J. 2018 Apr;285(8):1403-1418. PMID: 29498802